Digest Network Come funziona
Network
/
Società
Sp
Non verificato

Spruce Biosciences, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteWeb e Social Network

17 comunicati stampa

Guarda tutti i comunicati
10/11/2025
Mercato azionario
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Fonte
Spruce Biosciences, Inc.
Emittente
Business Wire
1.00
0
08/10/2025
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Mercato del lavoro
Finanza
Spruce Biosciences Announces $50.0 Million Private Placement Financing
Fonte
Spruce Biosciences, Inc.
Emittente
Business Wire
1.00
0
06/10/2025
Scienza
Farmaceutica
Vetrine/Shopping
Biotecnologia
Infanzia
Medicina - Varie
Assistenza all'Infanzia
Igiene alimentare
Salute
Industria
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)
Fonte
Spruce Biosciences, Inc.
Emittente
Business Wire
1.00
0
15/09/2025
Biotecnologia
Farmaceutica
Salute
Spruce Biosciences Resumes Trading on the Nasdaq Capital Market
Fonte
Spruce Biosciences, Inc.
Emittente
Business Wire
1.00
0
14/08/2025
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Mercato azionario
Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Fonte
Spruce Biosciences, Inc.
Emittente
Business Wire
1.00
0
14/08/2025
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB)
Fonte
Spruce Biosciences, Inc.
Emittente
Business Wire
1.00
0
24/07/2025
Biotecnologia
Farmaceutica
Salute
Finanza
Spruce Biosciences Announces Reverse Stock Split
Fonte
Spruce Biosciences, Inc.
Emittente
Business Wire
1.00
0
12/06/2025
Biotecnologia
Farmaceutica
Salute
Web e Social Network
Finanza
Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market
Fonte
Spruce Biosciences, Inc.
Emittente
Business Wire
1.00
0
06/05/2025
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Farmaceutica
Salute
Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Fonte
Spruce Biosciences, Inc.
Emittente
Business Wire
1.00
0
15/04/2025
Industria
Mercato del lavoro
Web e Social Network
Telefonia e Varie
Salute
Igiene alimentare
Medicina - Varie
Farmaceutica
Biotecnologia
Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
Fonte
Spruce Biosciences, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0